National Institute on Drug Abuse; Amended Notice of Meeting, 62097 [2023-19406]

Download as PDF Federal Register / Vol. 88, No. 173 / Friday, September 8, 2023 / Notices approximately 1 week after the public meeting. FDA has verified the website addresses in this document, as of the date this document publishes in the Federal Register, but websites are subject to change over time. Transcripts: Please be advised that as soon as a transcript of the public meeting is available, it will be accessible at https://www.regulations.gov. A link to the transcript will also be available at https://www.fda.gov/about-fda/officeimmunology-and-inflammationdivision-rheumatology-and-transplantmedicine-drtm. Dated: September 1, 2023. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2023–19405 Filed 9–7–23; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Advisory Council on Blood Stem Cell Transplantation Health Resources and Services Administration (HRSA), Department of Health and Human Services. ACTION: Notice. AGENCY: In accordance with the Federal Advisory Committee Act, this notice announces that the Secretary’s Advisory Council on Blood Stem Cell Transplantation (ACBSCT or Advisory Council) has scheduled public meetings. Information about the Advisory Council and the agenda for these meetings can be found on the ACBSCT website at: https://bloodstemcell.hrsa.gov/about/ advisory-council. DATES: Thursday, September 28, 2023, 2:00 p.m.–6:00 p.m. Eastern Standard Time; and Thursday, October 26, 2023, 2:00 p.m.–6:00 p.m. Eastern Standard Time. SUMMARY: Both meetings will be held virtually by webinar. A link to register and join each meeting will be posted at least 10 days prior to the meeting date at: https://bloodstemcell.hrsa.gov/ about/advisory-council. FOR FURTHER INFORMATION CONTACT: Shelley Tims Grant, Designated Federal Official, at the HRSA Health Systems Bureau, Division of Transplantation, 5600 Fishers Lane, 8W–67, Rockville, MD 20857; 301–443–8036; or ACBSCTHRSA@hrsa.gov. SUPPLEMENTARY INFORMATION: The Advisory Council provides advice and lotter on DSK11XQN23PROD with NOTICES1 ADDRESSES: VerDate Sep<11>2014 17:30 Sep 07, 2023 Jkt 259001 recommendations to the Secretary of Health and Human Services on policy, program development, and other matters of significance concerning the activities under the authority of 42 U.S.C. 274k (section 379 of the Public Health Service Act), as amended, and Public Law 109–129, as amended. The Advisory Council may transmit its recommendations through the Administrator of HRSA on matters related to the activities of the C.W. Bill Young Cell Transplantation Program and National Cord Blood Inventory. The agenda for the September 28, 2023, meeting is being finalized and may include the following topics: the Department of Health and Human Services’ periodic review of the state of the science of using adult stem cells and birthing tissues to develop new types of therapies for patients, for the purpose of considering potential inclusion of such new therapies in the C.W. Bill Young Cell Transplantation Program; criteria for defining a high-quality cord blood unit for banking specifications; the unmet needs in blood stem cell transplantation and cellular therapy; strategies to improve rates of donation for adult blood stem cell donors; and other areas to increase blood stem cell donation and transplantation. The agenda for the October 26, 2023, meeting will be determined based on discussion, priorities, and/or action items from the September 28, 2023 meeting. All agenda items will be posted on the Advisory Council’s website no later than 10 days prior to the respective meeting dates. Agenda items are subject to change as priorities dictate. Refer to the Advisory Council’s website for any updated information concerning the meeting. Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meetings; oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to the Advisory Council should be sent to Shelley Tims Grant, using the contact information above at least 3 business days prior to the meeting. Individuals who plan to attend and need special assistance or other reasonable accommodations should notify the Advisory Council at the address and phone number listed above at least 10 business days prior to the meeting. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2023–19398 Filed 9–7–23; 8:45 am] BILLING CODE 4165–15–P PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 62097 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Advisory Council on Drug Abuse, September 12, 2023, 10:30 a.m. to September 12, 2023, 05:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 which was published in the Federal Register on August 21, 2023, FR Doc 2023– 17889, 88 FR 56847. This notice is being amended to change the open session start time from 12:45 p.m. to 1:00 p.m. The open session will now be held from 1:00 p.m. to 5:00 p.m. on September 12, 2023. The meeting is partially closed to the public. Dated: September 1, 2023. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–19406 Filed 9–7–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Notice of Meeting for the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) Substance Abuse and Mental Health Services Administration, Department of Health and Human Services. ACTION: Notice. AGENCY: The Secretary of Health and Human Services announces a meeting of the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC). The meeting will provide information on federal efforts related to serious mental illness (SMI) and serious emotional disturbance (SED). DATES: October 18, 2023, 10:00 a.m. to 4:00 p.m. (EDT)/Open. ADDRESSES: The meeting is open to the public and can be accessed virtually only by accessing: https:// www.zoomgov.com/j/1608742409? pwd=NjdoRlpGU2NoOH paTzZVWXR3N0k4UT09, or by dialing 646–828–7666, webinar ID: 160 874 2409, passcode: 446018. Agenda with call-in information will be posted on the SUMMARY: E:\FR\FM\08SEN1.SGM 08SEN1

Agencies

[Federal Register Volume 88, Number 173 (Friday, September 8, 2023)]
[Notices]
[Page 62097]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-19406]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Advisory Council on Drug Abuse, September 12, 2023, 10:30 a.m. to 
September 12, 2023, 05:00 p.m., National Institutes of Health, 
Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 
which was published in the Federal Register on August 21, 2023, FR Doc 
2023-17889, 88 FR 56847.
    This notice is being amended to change the open session start time 
from 12:45 p.m. to 1:00 p.m. The open session will now be held from 
1:00 p.m. to 5:00 p.m. on September 12, 2023. The meeting is partially 
closed to the public.

    Dated: September 1, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-19406 Filed 9-7-23; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.